Inhibiting TLR2 activation attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer’s disease
- 1 November 2016
- journal article
- research article
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 58, 191-200
Abstract
No abstract availableKeywords
Funding Information
- Enterprise Ireland
- Opsona Therapeutics (11/PI/10154)
- Science Foundation Ireland
This publication has 33 references indexed in Scilit:
- Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microgliaNature Communications, 2013
- Hypothalamic neuronal toll-like receptor 2 protects against age-induced obesityScientific Reports, 2013
- Novel age-dependent learning deficits in a mouse model of Alzheimer's disease: Implications for translational researchNeurobiology of Aging, 2011
- Interleukin-1α and HMGB1 Mediate Hippocampal Dysfunction in SIGIRR-Deficient MiceThe Journal of Neuroscience, 2011
- RAGE‐dependent signaling in microglia contributes to neuroinflammation, Aβ accumulation, and impaired learning/memory in a mouse model of Alzheimer's diseaseThe FASEB Journal, 2009
- CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial ActivationThe Journal of Neuroscience, 2009
- Toll-Like Receptor 2 Acts as a Natural Innate Immune Receptor to Clear Amyloid β1–42and Delay the Cognitive Decline in a Mouse Model of Alzheimer's DiseaseThe Journal of Neuroscience, 2008
- Anti-amyloid beta protein antibody passage across the blood–brain barrier in the SAMP8 mouse model of Alzheimer's disease: An age-related selective uptake with reversal of learning impairmentExperimental Neurology, 2007
- Identification of functional domains in the formyl peptide receptor‐like 1 for agonist‐induced cell chemotaxisThe FEBS Journal, 2005
- Passage of amyloid β protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s diseasePeptides, 2002